| Literature DB >> 17040111 |
Abstract
Staphylococci are among the most frequently encountered pathogens in both the inpatient and the outpatient setting. Management of infections caused by these organisms is complicated by the increasingly common resistance of staphylococcal pathogens to commonly used antibacterials. As a consequence, novel approaches to prevention and treatment are urgently required. Such approaches include the development of vaccines and immunoglobulin preparations targeted at virulence factors expressed in vivo by staphylococci. This article reviews the biopharmaceutical progress made to date in this field and suggests approaches to further progress.Entities:
Mesh:
Substances:
Year: 2006 PMID: 17040111 DOI: 10.2165/00003495-200666140-00002
Source DB: PubMed Journal: Drugs ISSN: 0012-6667 Impact factor: 9.546